Patients Foregoing Treatment Due to Cost
Occasionally I come across articles that truly pull on your heart strings and this is certainly one of them.
Costly drugs force life, death decisions - Yahoo! News:
The article covers patients who forego treatment due to costs. I should point out though that these are primarily patients deciding that the highest cost of the drug is not worth a few months of possible extended life. It isn’t necessarily that they can’t afford it but more that the cost isn’t worth the benefit.
One of the downsides of biologics is the high costs. These materials are much more expensive and difficult to produce. One of the major roadblocks to generic version is the lack of agreement on what testing is necessary for such approvals. While Europe is well on its way to having a process in place, the FDA still seems to be waiting around for something to occur rather than taking the lead and setting up a process to use to approve these sorts of drugs regardless of what they are called. Whether you call them follow on protein products or you call them generic biologics, the bottom line is there needs to be a process for this to happen and sooner rather than later.
Technorati Tags: biogenerics, drug cost, generic
Related Posts:
Bookmark it with:
| 
del.icio.us
| 
Digg it
| 
Furl
| 
Simpy
| 
Spurl
| 
My Yahoo!
|
